Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.
about
Pathogenesis of human immunodeficiency virus infectionHigh-throughput profiling of anti-glycan humoral responses to SIV vaccination and challengeResolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccinesLocation-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivityMapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate.Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infectionEpitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128).Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques.The trail of my studies on glycoproteins from enterokinase to tumor markers.A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody.Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.
P2860
Q24634681-30B5AABC-7B22-45EA-86DA-A8D37C733D12Q30354064-3016BFEF-4788-478B-97F5-6757ED99F7CBQ33431143-94E2A632-BD8A-4EAA-97B6-C2763D4DFAC9Q33785035-F13F6D31-6117-458D-9E74-936776BD1B7FQ33785510-1168BD25-40ED-4F64-BDC3-DE7005203EA8Q33967039-9D6898CA-9E62-465C-9E02-DB0805FD7B32Q34458024-91B941C7-A370-4684-8D9D-06E64DD06A8DQ35837798-48CB4BDA-E147-4ACF-8785-E8A769CD36D4Q36178544-1781C3E4-5388-4285-ABAA-03F439E3EC79Q36628256-82B7E6F0-8592-4E38-AAE1-CDD4EABA4F75Q36702206-14E4EF16-869C-445A-A6E1-7795838917C8Q37765397-CD63B446-55D1-480F-9FB8-ABF42C3BC67FQ40038304-105532F4-1BC8-44BB-AB42-E833230FA9EDQ40789473-C8876CA7-1528-43AE-941D-53628331E4D5Q46202850-D001D6FA-EFF5-4442-8E32-2657D5B58922
P2860
Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Broadly neutralizing antibodie ...... human immunodeficiency virus.
@en
type
label
Broadly neutralizing antibodie ...... human immunodeficiency virus.
@en
prefLabel
Broadly neutralizing antibodie ...... human immunodeficiency virus.
@en
P2093
P2860
P1433
P1476
Broadly neutralizing antibodie ...... human immunodeficiency virus.
@en
P2093
Arendrup M
Mathiesen L
Nielsen JO
Olofsson S
P2860
P304
P407
P577
1991-12-01T00:00:00Z